

Ryan K Shields

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9724205/publications.pdf>

Version: 2024-02-01

120
papers

6,189
citations

66234

42
h-index

74018

75
g-index

124
all docs

124
docs citations

124
times ranked

5573
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 1615-1618.	2.9	362
2	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	347
3	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> _{KPC-3} Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	334
4	Colistin-Resistant <i>Acinetobacter baumannii</i> : Beyond Carbapenem Resistance. <i>Clinical Infectious Diseases</i> , 2015, 60, 1295-1303.	2.9	315
5	Performance of <i>Candida</i> Real-time Polymerase Chain Reaction, β -D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2012, 54, 1240-1248.	2.9	247
6	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 110-120.	2.9	224
7	Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	203
8	Mutations in <i>bla</i> _{KPC-3} That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	154
9	The Presence of an <i>FKS</i> Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4862-4869.	1.4	152
10	Comparison of an <i>Aspergillus</i> Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2011, 52, 1218-1226.	2.9	125
11	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	122
12	Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Infections among Solid Organ Transplant Recipients. <i>PLoS ONE</i> , 2012, 7, e52349.	1.1	118
13	Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2371-2377.	1.4	116
14	Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. <i>PLoS ONE</i> , 2016, 11, e0153247.	1.1	107
15	Effects of <i>Klebsiella pneumoniae</i> Carbapenemase Subtypes, Extended-Spectrum β -Lactamases, and Porin Mutations on the <i>In Vitro</i> Activity of Ceftazidime-Avibactam against Carbapenem-Resistant <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5793-5797.	1.4	104
16	Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx101.	0.4	103
17	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4443-4451.	1.4	99
18	Caspofungin MICs Correlate with Treatment Outcomes among Patients with <i>Candida glabrata</i> Invasive Candidiasis and Prior Echinocandin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3528-3535.	1.4	93

#	ARTICLE	IF	CITATIONS
19	<i>Klebsiella pneumoniae</i> Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β -Lactamase Protein Engineering. <i>MBio</i> , 2017, 8, .	1.8	93
20	Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7601-7605.	1.4	89
21	Mutations of the <i>ompK36</i> Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing <i>Klebsiella pneumoniae</i> Strains to Doripenem and Doripenem-Colistin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5258-5265.	1.4	87
22	Evaluation of the <i>In Vitro</i> Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3227-3231.	1.4	85
23	<i>In Vitro</i> Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	84
24	Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	72
25	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 667-671.	2.9	71
26	The Combination of Doripenem and Colistin Is Bactericidal and Synergistic against Colistin-Resistant, Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3395-3398.	1.4	69
27	High mortality rates among solid organ transplant recipients infected with extensively drug-resistant <i>Acinetobacter baumannii</i> : using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 246-252.	0.8	67
28	Clinical perspectives on echinocandin resistance among <i>Candida</i> species. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 514-522.	1.3	66
29	Evolution of Outbreak-Causing Carbapenem-Resistant <i>Klebsiella pneumoniae</i> ST258 at a Tertiary Care Hospital over 8 Years. <i>MBio</i> , 2019, 10, .	1.8	66
30	Posaconazole Serum Concentrations among Cardiothoracic Transplant Recipients: Factors Impacting Trough Levels and Correlation with Clinical Response to Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1308-1311.	1.4	62
31	Paradoxical Effect of Caspofungin against <i>Candida</i> Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2641-2647.	1.4	61
32	Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	61
33	Real-World Experience with Echinocandin MICs against <i>Candida</i> Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1897-1906.	1.4	59
34	<i>Staphylococcus aureus</i> infections in the early period after lung transplantation: Epidemiology, risk factors, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1199-1206.	0.3	57
35	Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β -Lactams for Major Gram-Negative Bacterial Pathogens. <i>Clinical Infectious Diseases</i> , 2017, 65, 738-745.	2.9	56
36	Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in <i>Enterobacter cloacae</i> Complex Following Exposure to Cefepime. <i>Clinical Infectious Diseases</i> , 2020, 71, 2713-2716.	2.9	56

#	ARTICLE	IF	CITATIONS
37	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	55
38	Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant <i>Candida glabrata</i> Strains and Echinocandin Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6361-6365.	1.4	54
39	Rapid Detection of FKS -Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6573-6577.	1.4	53
40	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in <i>Enterobacter cloacae</i> Due to AmpC R2 Loop Deletion. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	51
41	Characterization of Porin Expression in <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>K. pneumoniae</i> Identifies Isolates Most Susceptible to the Combination of Colistin and Carbapenems. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2147-2153.	1.4	50
42	Rate of FKS Mutations among Consecutive <i>Candida</i> Isolates Causing Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7465-7470.	1.4	48
43	Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. <i>PLoS ONE</i> , 2017, 12, e0173286.	1.1	46
44	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible <i>Pseudomonas aeruginosa</i> in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 2045-2052.	2.9	43
45	Fluconazole versus an echinocandin for <i>Candida glabrata</i> fungaemia: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 922-926.	1.3	42
46	Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx102.	0.4	42
47	Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3187-3192.	1.4	41
48	Cefiderocol for the Treatment of Infections Due to Metallo- β -lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies. <i>Clinical Infectious Diseases</i> , 2022, 75, 1081-1084.	2.9	41
49	In Vitro Responses of <i>Acinetobacter baumannii</i> to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1195-1199.	1.4	40
50	Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. <i>Microbial Drug Resistance</i> , 2022, 28, 398-407.	0.9	40
51	Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017. <i>Clinical Infectious Diseases</i> , 2021, 73, e4521-e4530.	2.9	39
52	Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- β -Lactamase-Producing Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5208-5214.	1.4	38
53	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, 416-426.	2.9	37
54	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	36

#	ARTICLE	IF	CITATIONS
55	Use of ceftaroline after glycopeptide failure to eradicate methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia with elevated vancomycin minimum inhibitory concentrations. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 557-563.	1.1	35
56	Aztreonam Combination Therapy: An Answer to Metallo- β -Lactamase-Producing Gram-Negative Bacteria?. <i>Clinical Infectious Diseases</i> , 2020, 71, 1099-1101.	2.9	35
57	Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing <i>Klebsiella pneumoniae</i> Strains with Various <i>ompK36</i> Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3521-3525.	1.4	34
58	The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. <i>BMC Infectious Diseases</i> , 2016, 16, 655.	1.3	33
59	Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteriuria. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3100-3104.	1.4	31
60	<i>In Vitro</i> Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	31
61	<i>In Vitro</i> Evolution of Cefiderocol Resistance in an NDM-Producing <i>Klebsiella pneumoniae</i> Due to Functional Loss of <i>CirA</i> . <i>Microbiology Spectrum</i> , 2021, 9, e0177921.	1.2	31
62	Spontaneous Mutational Frequency and <i>FKS</i> Mutation Rates Vary by Echinocandin Agent against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30
63	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	29
64	Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, e1754-e1757.	2.9	27
65	Contemporary Perspective on the Treatment of <i>Acinetobacter baumannii</i> Infections: Insights from the Society of Infectious Diseases Pharmacists. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2177-2202.	1.8	27
66	Doripenem MICs and <i>ompK36</i> Porin Genotypes of Sequence Type 258, KPC-Producing <i>Klebsiella pneumoniae</i> May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1797-1801.	1.4	25
67	Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 114856.	0.8	25
68	Spontaneous fungal peritonitis: a devastating complication of cirrhosis. <i>Mycoses</i> , 2015, 58, 387-393.	1.8	24
69	Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae <i>In Vitro</i> or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	22
70	Structural Characterization of the D179N and D179Y Variants of KPC-2 β -Lactamase: Ω -Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0241421.	1.4	22
71	Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3090-3095.	1.4	21
72	Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible <i>Citrobacter</i> spp. at a Tertiary Health Care Center over 2 Decades. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	21

#	ARTICLE	IF	CITATIONS
73	Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2022, 74, 395-406.	2.9	19
74	Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia. <i>Clinical Infectious Diseases</i> , 2022, 75, 710-714.	2.9	19
75	Patient-to-Patient Transmission of <i>Klebsiella pneumoniae</i> Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	18
76	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	18
77	KPC-Producing <i>Klebsiella pneumoniae</i> Strains That Harbor AAC(6)-Ib Exhibit Intermediate Resistance to Amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7597-7600.	1.4	17
78	Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant <i>Klebsiella pneumoniae</i> in a tandem in vitro time-kill/in vivo Galleria-Mellonella survival model analysis. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105852.	1.1	17
79	Five-Minute Exposure to Caspofungin Results in Prolonged Postantifungal Effects and Eliminates the Paradoxical Growth of <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3598-3602.	1.4	16
80	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antibiotics</i> , 2021, 10, 880.	1.5	16
81	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3558-3562.	1.4	14
82	Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	14
83	Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study: Table A1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3585-3587.	1.3	13
84	1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant <i>K. pneumoniae</i> and <i>P. aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S419-S420.	0.4	13
85	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of <i>Klebsiella pneumoniae</i> in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	13
86	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3023-3028.	1.3	13
87	High-Level Carbapenem Resistance in OXA-232-Producing <i>Raoultella ornithinolytica</i> Triggered by Ertapenem Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	11
88	Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0212421.	1.4	11
89	Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016, 2, 10.	1.5	10
90	Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Meningitis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa549.	0.4	10

#	ARTICLE	IF	CITATIONS
91	Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 982-986.	1.5	9
92	Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Infection and Immunity</i> , 2022, 90, e0000122.	1.0	8
93	Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for <i>FKS</i> -Associated Echinocandin Resistance in <i>Candida glabrata</i> Septic Arthritis and Osteomyelitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
94	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in <i>Klebsiella pneumoniae</i> ST258. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2203-2208.	1.3	3
95	<i>Candida</i> Biofilm: Clinical Implications of Recent Advances in Research. <i>Current Fungal Infection Reports</i> , 2014, 8, 72-80.	0.9	2
96	Ceftolozane/tazobactam for refractory <i>P. aeruginosa</i> endocarditis: A case report and pharmacokinetic analysis. <i>Journal of Infection and Chemotherapy</i> , 2021, 28, 87-90.	0.8	2
97	Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy (OPAT) Program Failure Among Intravenous Drug Users (IVDUs). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
98	Rapid Emergence of Ceftazidime-Avibactam Resistance Due to blaKPC-3 Mutations During Treatment (tx) of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> (CRKp) Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
99	2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance. <i>Open Forum Infectious Diseases</i> , 2018, 5, S729-S729.	0.4	1
100	2420. A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S723-S724.	0.4	1
101	Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114954.	0.8	1
102	Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa571.	0.4	1
103	Hydrolytic activity of KPC-producing <i>Klebsiella pneumoniae</i> clinical isolates. <i>Journal of Chemotherapy</i> , 2022, 34, 345-346.	0.7	1
104	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical Isolates. <i>Phage</i> , 2022, 3, 50-58.	0.8	1
105	Outcomes of <i>Candida</i> Empyema Correlate with Source of Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
106	Outcomes Comparing Initial Fluconazole to Micafungin in ICU Patients with Candidemia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
107	Retrospective Study of Outcomes Comparing Initial Treatment with Fluconazole or Micafungin in Immunosuppressed Patients with Candidemia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
108	Daptomycin Non-susceptible VRE: Problematic Pathogen or Misclassified Microbe?. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
109	Impact of Rectal Colonization With Highly Drug-Resistant Enterobacteriaceae on Post-Transplant Infections: The Carbapenem-Resistant Enterobacteriaceae Carriage in Solid Organ Transplant (CREST) Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
110	Emerging Waves of Carbapenem Resistance Among Gram-Negative Pathogens at a Tertiary Center. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
111	Clinical Outcomes of Bloodstream Infections Due to Vancomycin-Resistant <i>Enterococcus faecium</i> . <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
112	Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. <i>Open Forum Infectious Diseases</i> , 2017, 4, S297-S297.	0.4	0
113	2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses. <i>Open Forum Infectious Diseases</i> , 2018, 5, S724-S724.	0.4	0
114	1064. Clinical Outcomes of Daptomycin in Combination With Ceftaroline or Anti-Staphylococcal Penicillins for Patients With Persistent MRSA Bacteremia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S318-S318.	0.4	0
115	1528. A Real-World Perspective on Treatment of CRE UTIs With Oral Agents. <i>Open Forum Infectious Diseases</i> , 2018, 5, S474-S474.	0.4	0
116	2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Isolates Causing Persistent Bacteremia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S717-S718.	0.4	0
117	247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria. <i>Open Forum Infectious Diseases</i> , 2018, 5, S105-S105.	0.4	0
118	357. <i>Aspergillus</i> Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program Using Azole Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S140-S140.	0.4	0
119	706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing <i>Klebsiella pneumoniae</i> (Kp). <i>Open Forum Infectious Diseases</i> , 2018, 5, S254-S254.	0.4	0
120	2033. Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients At-Risk for Sepsis due to Invasive Candidiasis (IC). <i>Open Forum Infectious Diseases</i> , 2018, 5, S592-S593.	0.4	0